North American Scientific Adds VP Marketing to Senior Team
15 Julio 2008 - 5:00AM
Business Wire
North American Scientific (NASDAQ:NASM) announced today that it has
appointed Robin Gibbs to the position of Vice President of
Marketing. Ms. Gibbs, formerly a Vice President of Global Franchise
Management for Edwards Lifesciences, will lead the marketing team
for the company�s growing Radiation Sources division, including the
new ClearPath HDR and ClearPath CR devices which allow customized
local radiation dosing for the breast cancer patient. Ms. Gibbs
will report directly to John Rush, President and CEO of North
American Scientific. �Robin brings 30 years of commercial
experience with clinical diagnostics and medical devices to our
organization,� said Mr. Rush. �Her global strategic marketing
skills will add the appropriate level of expertise to the senior
team as we develop and implement strategies to expand our business
worldwide and prepare for launch of our new ClearPath products for
the Breast Cancer market.� Ms. Gibbs joins North American
Scientific from MedX3, LLC, a marketing and business development
firm where she held a principal position. In her career, she has
held positions with significant responsibility including roles as
Vice President of Global Franchise Management, Vice President of
Global Marketing Cardiovascular Surgery, Vice president of Global
Marketing Heart Valve Therapy, and Director of National Accounts.
Ms. Gibbs began her career in sales and sales management positions
with American Hospital Supply and Baxter Healthcare. About North
American Scientific North American Scientific is a medical device
company focused on developing products which deliver local
controlled radiation therapy for cancer. Its innovative products
allow patients to be treated effectively with a shortened course of
treatment and reduced side effects. Current products include the
Prospera� Iodine and Palladium seeds and SurTRAK� needles and
strands used primarily in the treatment of prostate cancer.
Additionally, the Company has been gaining clinical experience with
its ClearPath� multi-channel catheter device for local radiation
delivery in the breast cancer patient. The ClearPath family of
products are the only such devices approved for both high dose and
continuous release, or low dose, local radiation treatments for
breast cancer. The devices are designed to provide flexible,
precise dose customization and unparalleled patient comfort in a
shortened, effective course of treatment. Please visit
www.nasmedical.com for more information.
North American Scientific (MM) (NASDAQ:NASM)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
North American Scientific (MM) (NASDAQ:NASM)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about North American Scientific (MM) (NASDAQ): 0 recent articles
Más de North American Scientific Artículos de Noticias